Open Collections

UBC Faculty Research and Publications

HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study Harris, Marianne; Ganase, Bruce; Watson, Birgit; Harrigan, Paul Richard; Montaner, Julio; Hull, Mark W.

Abstract

Background: As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and pharmacokinetics of once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) with darunavir. Methods: A single arm, open-label 48-week study was conducted of regimen simplification to E/C/F/TDF plus darunavir 800 mg daily from stable therapy including two nucleoside/nucleotide reverse transcriptase inhibitors, a ritonavir-boosted protease inhibitor, and an integrase inhibitor. Participants had plasma HIV viral load consistently

Item Metadata

Title
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
Creator
Harris, Marianne; Ganase, Bruce; Watson, Birgit; Harrigan, Paul Richard; Montaner, Julio; Hull, Mark W.
Contributor
British Columbia Centre for Excellence in HIV/AIDS
Publisher
BioMed Central
Date Issued
2017-11-02
Description
Background: As a simplification strategy for treatment-experienced HIV-infected patients who have achieved virologic suppression on a multi-drug, multi-class antiretroviral regimen, the aim of this study was to evaluate the safety, efficacy, and pharmacokinetics of once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) with darunavir. Methods: A single arm, open-label 48-week study was conducted of regimen simplification to E/C/F/TDF plus darunavir 800 mg daily from stable therapy including two nucleoside/nucleotide reverse transcriptase inhibitors, a ritonavir-boosted protease inhibitor, and an integrase inhibitor. Participants had plasma HIV viral load consistently
Subject
HIV; Antiretrovirals; Elvitegravir; Cobicistat; Darunavir
Genre
Article
Type
Text
Language
eng
Date Available
2017-12-11
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0361811
URI
http://hdl.handle.net/2429/63920
Affiliation
Medicine, Faculty of; Other UBC; Family Practice, Department of
Citation
AIDS Research and Therapy. 2017 Nov 02;14(1):59
Publisher DOI
10.1186/s12981-017-0185-4
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s)
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)